Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases

Canadian Journal of Cardiology

Volumn 31, Issue 4, 2015, Pages 416-429

  Dupuis, Jocelyn ^a   Guazzi, Marco ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V; VASODILATOR AGENT;

BREATHING; CAPILLARY; CONSENSUS; EXERCISE; FUNCTIONAL STATUS; GAS DIFFUSION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE; HEMODYNAMICS; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG CAPILLARY; LUNG CIRCULATION; LUNG INJURY; LUNG MECHANICS; LUNG PRESSURE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; TISSUE REGENERATION; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; LUNG WEDGE PRESSURE; PHYSIOLOGY; VASCULAR REMODELING;

HUMANS; HYPERTENSION, PULMONARY; PULMONARY CIRCULATION; PULMONARY WEDGE PRESSURE; VASCULAR REMODELING; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84924789019     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.10.012     Document Type: Review

References (100)

1. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D34-41.
2. Rich J.D., Shah S.J., Swamy R.S., Kamp A., Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011, 139:988-993.
3. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. JAm Coll Cardiol 2009, 53:1119-1126.
4. Kalogeropoulos A.P., Siwamogsatham S., Hayek S., et al. Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients. JAm Heart Assoc 2014, 3:e000363.
5. Janda S., Shahidi N., Gin K., Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 2011, 97:612-622.
6. Bursi F., McNallan S.M., Redfield M.M., et al. Pulmonary pressures and death in heart failure: a community study. JAm Coll Cardiol 2012, 59:222-231.
7. Miller W.L., Grill D.E., Borlaug B.A. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013, 1:290-299.
8. Gerges C., Gerges M., Lang M.B., et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 2013, 143:758-766.
9. Azarbar S., Dupuis J. Lung capillary injury and repair in left heart disease: a new target for therapy?. Clin Sci (Lond) 2014, 127:65-76.
10. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. JAm Coll Cardiol 2001, 37:183-188.
11. Chatterjee N.A., Upadhyay G.A., Singal G., et al. Pre-capillary pulmonary hypertension and right ventricular dilation predict clinical outcome in cardiac resynchronization therapy. JACC Heart Fail 2014, 2:230-237.
12. West J.B., Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation 1995, 92:622-631.
13. Gehlbach B.K., Geppert E. The pulmonary manifestations of left heart failure. Chest 2004, 125:669-682.
14. Guazzi M., Labate V., Cahalin L.P., Arena R. Cardiopulmonary exercise testing reflects similar pathophysiology and disease severity in heart failure patients with reduced and preserved ejection fraction. Eur J Prev Cardiol 2013, 21:847-854.
15. Guazzi M., Cahalin L.P., Arena R. Cardiopulmonary exercise testing as a diagnostic tool for the detection of left-sided pulmonary hypertension in heart failure. JCard Fail 2013, 19:461-467.
16. Cahalin L.P., Chase P., Arena R., et al. Ameta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev 2013, 18:79-94.
17. Jasmin J.F., Calderone A., Leung T.K., Villeneuve L., Dupuis J. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res 2003, 58:621-631.
18. Chen Y., Guo H., Xu D., et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 2012, 59:1170-1178.
19. Huang W., Kingsbury M.P., Turner M.A., et al. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res 2001, 49:207-217.
20. Kapanci Y., Burgan S., Pietra G.G., Conne B., Gabbiani G. Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension. Am J Pathol 1990, 136:881-889.
21. Powell D.W., Mifflin R.C., Valentich J.D., et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999, 277:C1-9.
22. Dupuis J., Prefontaine A., Villeneuve L., et al. Bone marrow-derived progenitor cells contribute to lung remodelling after myocardial infarction. Cardiovasc Pathol 2007, 16:321-328.
23. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. JCard Fail 2008, 14:695-702.
24. Jiang B.H., Tardif J.C., Sauvageau S., et al. Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure. JCard Fail 2010, 16:679-688.
25. Chabot A., Jiang B.H., Shi Y., Tardif J.C., Dupuis J. Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. BMC Cardiovasc Disord 2011, 11:72.
26. Jasmin J.F., Mercier I., Hnasko R., et al. Lung remodeling and pulmonary hypertension after myocardial infarction: Pathogenic role of reduced caveolin expression. Cardiovasc Res 2004, 63:747-755.
27. Guazzi M., Marenzi G., Alimento M., Contini M., Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997, 95:1930-1936.
28. Fang J.C., DeMarco T., Givertz M.M., et al. World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult-a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. JHeart Lung Transplant 2012, 31:913-933.
29. Vachiéry J.L., Adir Y., Barberà J.A., et al. Pulmonary hypertension due to left heart diseases. JAm Coll Cardiol 2013, 62:D100-D108.
30. Ryan J.J., Rich J.D., Thiruvoipati T., et al. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 2012, 163:589-594.
31. Robbins I.M., Hemnes A.R., Pugh M.E., et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014, 7:116-122.
32. Naeije R., Vachiery J.L., Yerly P., Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013, 41:217-223.
33. Tedford R.J., Beaty C.A., Mathai S.C., et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. JHeart Lung Transplant 2014, 33:289-297.
34. Costard-Jackle A., Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. JAm Coll Cardiol 1992, 19:48-54.
35. Solomonica A., Burger A.J., Aronson D. Hemodynamic determinants of dyspnea improvement in acute decompensated heart failure. Circ Heart Fail 2013, 6:53-60.
36. Merlos P., Nunez J., Sanchis J., et al. Echocardiographic estimation of pulmonary arterial systolic pressure in acute heart failure. Prognostic implications. Eur J Int Med 2013, 24:562-567.
37. Ather S., Chan W., Bozkurt B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JAm Coll Cardiol 2012, 59:998-1005.
38. Salamon J.N., Kelesidis I., Msaouel P., et al. Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension. JCard Fail 2014, 20:467-475.
39. Lam C.S., Borlaug B.A., Kane G.C., et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009, 119:2663-2670.
40. Guazzi M., Borlaug B.A. Pulmonary hypertension due to left heart disease. Circulation 2012, 126:975-990.
41. Rosenkranz S., Ghofrani H.A., Grunig E., Hoeper M.M. Cologne consensus conference on pulmonary hypertension. Int J Cardiol 2011, 154(suppl 1):S1-2.
42. Hurdman J., Condliffe R., Elliot C.A., et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013, 41:1292-1301.
43. Anjan V.Y., Loftus T.M., Burke M.A., et al. Prevalence, clinical phenotype, and outcomes associated with normal b-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 2012, 110:870-876.
44. Rabinovitz A., Raiszadeh F., Zolty R. Association of hyponatremia and outcomes in pulmonary hypertension. JCard Fail 2013, 19:550-556.
45. van Empel V.P., Kaufmann B.A., Bernheim A.M., et al. Interaction between pulmonary hypertension and diastolic dysfunction in an elderly heart failure population. JCard Fail 2014, 20:98-104.
46. Aronson D., Eitan A., Dragu R., Burger A.J. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail 2011, 4:644-650.
47. Champion H.C., Michelakis E.D., Hassoun P.M. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009, 120:992-1007.
48. Damy T., Kallvikbacka-Bennett A., Goode K., et al. Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. JCard Fail 2012, 18:216-225.
49. Guazzi M., Bandera F., Pelissero G., et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol 2013, 305:H1373-H1381.
50. Melenovsky V., Hwang S.J., Lin G., Redfield M.M., Borlaug B.A. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014, 35:3452-3462.
51. Butler J., Chomsky D.B., Wilson J.R. Pulmonary hypertension and exercise intolerance in patients with heart failure. JAm Coll Cardiol 1999, 34:1802-1806.
52. Guazzi M., Pepi M., Maltagliati A., et al. How the two sides of the heart adapt to graded impedance to venous return with head-up tilting. JAm Coll Cardiol 1995, 26:1732-1740.
53. Tyberg J.V., Taichman G.C., Smith E.R., et al. The relationship between pericardial pressure and right atrial pressure: an intraoperative study. Circulation 1986, 73:428-432.
54. Atherton J.J., Moore T.D., Lele S.S., et al. Diastolic ventricular interaction in chronic heart failure. Lancet 1997, 349:1720-1724.
55. Guazzi M., Gatto P., Giusti G., et al. Pathophysiology of cardiorenal syndrome in decompensated heart failure: Role of lung-right heart-kidney interaction. Int J Cardiol 2013, 169:379-384.
56. Mullens W., Abrahams Z., Francis G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. JAm Coll Cardiol 2009, 53:589-596.
57. Bock J.S., Gottlieb S.S. Cardiorenal syndrome: new perspectives. Circulation 2010, 121:2592-2600.
58. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999, 353:1838-1842.
59. Melenovsky V., Kotrc M., Borlaug B.A., et al. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. JAm Coll Cardiol 2013, 62:1660-1670.
60. Arena R., Myers J., Abella J., et al. Development of a ventilatory classification system in patients with heart failure. Circulation 2007, 115:2410-2417.
61. Guazzi M., Myers J., Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. JAm Coll Cardiol 2005, 46:1883-1890.
62. Wasserman K., Zhang Y.Y., Gitt A., et al. Lung function and exercise gas exchange in chronic heart failure. Circulation 1997, 96:2221-2227.
63. Lewis G.D., Shah R.V., Pappagianopolas P.P., Systrom D.M., Semigran M.J. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail 2008, 1:227-233.
64. Wada O., Asanoi H., Miyagi K., et al. Importance of abnormal lung perfusion in excessive exercise ventilation in chronic heart failure. Am Heart J 1993, 125:790-798.
65. Wensel R., Georgiadou P., Francis D.P., et al. Differential contribution of dead space ventilation and low arterial pCO2 to exercise hyperpnea in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2004, 93:318-323.
66. Myers J., Salleh A., Buchanan N., et al. Ventilatory mechanisms of exercise intolerance in chronic heart failure. Am Heart J 1992, 124:710-719.
67. Guazzi M., Reina G., Tumminello G., Guazzi M.D. Alveolar-capillary membrane conductance is the best pulmonary function correlate of exercise ventilation efficiency in heart failure patients. Eur J Heart Fail 2005, 7:1017-1022.
68. Leite J.J., Mansur A.J., de Freitas H.F., et al. Periodic breathing during incremental exercise predicts mortality in patients with chronic heart failure evaluated for cardiac transplantation. JAm Coll Cardiol 2003, 41:2175-2181.
69. Murphy R.M., Shah R.V., Malhotra R., et al. Exercise oscillatory ventilation in systolic heart failure: An indicator of impaired hemodynamic response to exercise. Circulation 2011, 124:1442-1451.
70. Puri S., Baker B.L., Dutka D.P., et al. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation 1995, 91:2769-2774.
71. Puri S., Dutka D.P., Baker B.L., Hughes J.M., Cleland J.G. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation 1999, 99:1190-1196.
72. Guazzi M., Oreglia I., Guazzi M.D. Insulin improves alveolar-capillary membrane gas conductance in type 2 diabetes. Diabetes Care 2002, 25:1802-1806.
73. Labate V., Bandera F., Generati G., et al. Impaired gas diffusion and RV to pulmonary circulation uncoupling limit exercise performance in heart failure patients. Circulation 2014, (abstract).
74. Magri D., Brioschi M., Banfi C., et al. Circulating plasma surfactant protein type B as biological marker of alveolar-capillary barrier damage in chronic heart failure. Circ Heart Fail 2009, 2:175-180.
75. Theodosiou M., Lim H.S. Exercise ventilatory parameters for the diagnosis of reactive pulmonary hypertension in patients with heart failure. JCard Fail 2014, 20:650-657.
76. Guazzi M., Agostoni P. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane. Clin Sci 1999, 96:17-22.
77. Agostoni P., Magini A., Andreini D., et al. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J 2005, 26:159-164.
78. Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail 2014, 7:367-377.
79. Kottenberg E., Dumont M., Frey U.H., et al. The minimally invasive mitraclip procedure for mitral regurgitation under general anaesthesia: immediate effects on the pulmonary circulation and right ventricular function. Anaesthesia 2014, 69:860-867.
80. Angel Gomez-Sanchez M., Saenz De La Calzada C., Escribano Subias P., et al. Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur J Heart Fail 2004, 6:615-617.
81. Jabbour A., Keogh A., Hayward C., Macdonald P. Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Eur J Heart Fail 2007, 9:674-677.
82. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116:1555-1562.
83. Behling A., Rohde L.E., Colombo F.C., et al. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. JCard Fail 2008, 14:189-197.
84. Tedford R.J., Hemnes A.R., Russell S.D., et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008, 1:213-219.
85. Guazzi M., Vicenzi M., Arena R., Guazzi M.D. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011, 124:164-174.
86. Pons J., Leblanc M.H., Bernier M., et al. Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation. JHeart Lung Transplant 2012, 31:1281-1287.
87. Guazzi M., Vicenzi M., Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail 2012, 14:82-90.
88. Dumitrescu D., Seck C., Mohle L., Erdmann E., Rosenkranz S. Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. Int J Cardiol 2012, 154:205-206.
89. Reichenbach A., Al-Hiti H., Malek I., et al. The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study. Int J Cardiol 2013, 168:60-65.
90. Urbanowicz T., Straburzynska-Migaj E., Katynska I., et al. Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil. Ann Transplant 2014, 19:325-330.
91. Bonderman D., Ghio S., Felix S.B., et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013, 128:502-511.
92. Bonderman D., Pretsch I., Steringer-Mascherbauer R., et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 2014, 146:1274-1285.
93. Murray F., MacLean M.R., Pyne N.J. Increased expression of the CGMP-inhibited camp-specific (PDE3) and CGMP binding CGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002, 137:1187-1194.
94. Melenovsky V., Al-Hiti H., Kazdova L., et al. Transpulmonary b-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. JAm Coll Cardiol 2009, 54:594-600.
95. Alaeddini J., Uber P.A., Park M.H., et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004, 94:1475-1477.
96. Lepore J.J., Maroo A., Bigatello L.M., et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127:1647-1653.
97. Guazzi M., Tumminello G., Di Marco F., Fiorentini C., Guazzi M.D. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. JAm Coll Cardiol 2004, 44:2339-2348.
98. Lewis G.D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115:59-66.
99. Guazzi M., Samaja M., Arena R., Vicenzi M., Guazzi M.D. Long-term use of sildenafil in the therapeutic management of heart failure. JAm Coll Cardiol 2007, 50:2136-2144.
100. Yin J., Kukucka M., Hoffmann J., et al. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 2011, 4:198-206.